Why are Telix Pharmaceuticals shares diving today?

Shares in this up-and-coming drug company are under pressure over law suits filed in the US.

Key points
  • Several law firms in the US have lodged class action claims against Telix.
  • They allege the company made misleading claims to the detriment of shareholders.
  • Telix is yet to respond to the claims.

Telix Pharmaceuticals Ltd (ASX: TLX) shares have dipped on Friday after news broke that several law firms had filed class actions against the company in the US.

Law firm Robbins Geller Rudman and Dowd was among the law firms that filed a claim and encouraged shareholders to join their push for damages.

Scientists working in the laboratory and examining results.

Image source: Getty Images

Claims the company made false statements

That firm's claim, Thomas v. Telix Pharmaceuticals Ltd, alleges the company and certain of its executives breached the US Securities Exchange Act of 1934 during the period 21 February 2025 through to 28 August 2025.

The law firm says on its website:

The Telix Pharmaceuticals class action lawsuit alleges that throughout the class period defendants made false and/or misleading statement and/or failed to disclose that: (i) defendants materially overstated the progress Telix Pharmaceuticals had made with regard to prostate cancer therapeutic candidates; and (ii) defendants materially overstated the quality of Telix Pharmaceuticals' supply chain and partners.

The suit further alleges that on 22 July 2025, the company "received a subpoena from the U.S. Securities and Exchange Commission (SEC) seeking various documents and information primarily relating to the Company's disclosures regarding the development of the Company's prostate cancer therapeutics candidates".

The law firm says the company's shares, which are also listed in the US, subsequently fell more than 13% across two trading days.

Then later on 28 August, the claim says Telix "disclosed that it received a Complete Response Letter from the U.S. Food and Drug Administration ("FDA") for the Biologics License Application for its product TLX250-CDx, which identified "\'deficiencies relating to the Chemistry, Manufacturing, and Controls (CMC) package"'.

The FDA additionally 'documented notices of deficiency (Form 483) issued to two third-party manufacturing and supply chain partners that will require remediation prior to resubmission,' according to the complaint.  The Telix Pharmaceuticals class action lawsuit alleges that on this news, the price of Telix Pharmaceuticals ADSs fell more than 21% over two trading sessions.

Other law firms that have lodged similar actions include Hagens Berman Shareholder Advocates and Berger Montague.

Telix is yet to make a statement to the ASX regarding the lawsuits.  

Telix shares were trading 4.3% lower on Friday at $14.34. The shares have traded as high as $31.97 over the past year.

Telix in mid-October reported third-quarter revenue of about $206 million, up 53% on the same period the previous year and upgraded its full-year revenue guidance to $800 to $820 million.  

The company was valued at $5.07 billion at the close of trade on Thursday. Telix has been contacted for comment.

Bell Potter recently said it had a $23 price target on Telix shares.

Motley Fool contributor Cameron England has positions in Telix Pharmaceuticals. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Could Telix Pharmaceuticals shares double in value over the next 12 months?

Find out if the ASX biotech stock is a buy, sell, or hold now.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

3 compelling reasons to consider buying Mesoblast shares

This company has a lot going on, plus strong revenues.

Read more »

Doctor with stethoscope typing on her computer.
Healthcare Shares

Are CSL shares a buy, hold, or sell at their 52-week high?

Investors have become much more optimistic about its future. But has the share price recovery gone too far?

Read more »